The accumulation of extracellular matrix proteins in the interstitial area is the final common feature of chronic kidney diseases. Accumulating evidence suggests that transforming growth factor (TGF)-b1 promotes the development of renal fibrosis. Heat shock protein (Hsp) 90 inhibitors have been shown to repress TGF-b1 signaling, but whether they inhibit renal fibrosis is unknown. The purpose of this study is to determine the therapeutic efficacy of Hsp90 inhibitor on renal fibrosis. In TGF-b1-treated HK2 cells and unilateral ureteral obstruction (UUO) kidneys, we found that 17-allylamino-17-demethoxygeldanamycin (17AAG), an Hsp90 inhibitor, decreased the expression of a-smooth muscle actin, fibronectin, and collagen I and largely restored the expression of E-cadherin. 17AAG inhibited TGF-b1-mediated phosphorylation of Smad2, Akt, glycogen synthase kinase-3b, and extracellular signal-regulated kinase in HK2 cells. Inhibition of Hsp90 also blocked TGF-b1-mediated induction of snail1. This 17AAG-induced reduction was completely restored by simultaneous treatment with proteasome inhibitor MG132. Furthermore, 17AAG blocked the interaction between Hsp90 and TGF-b type II receptor (TbRII) and promoted ubiquitination of TbRII, leading to the decreased availability of TbRII. Smurf2-specific siRNA reversed the ability of 17AAG to inhibit TGF-b1 signaling. The effect of 17AAG on TbRII expression and renal fibrosis was confirmed in UUO kidneys. These findings suggest that Hsp90 inhibitor prevents the development of renal fibrosis via a mechanism dependent on Smurf2-mediated degradation of TbRII.
Tubulointerstitial fibrosis is the final common manifestation of various chronic kidney diseases, and progressive accumulation of extracellular matrix (ECM) proteins in the interstitial area is a key feature. Although interstitial fibroblasts are considered the principal source of matrix production, 1,2 the role of epithelial-to-mesenchymal transition (EMT) of renal tubular epithelial cells has been implicated in accelerating fibrogenesis. 3 Among several growth factors and cytokines, transforming growth factor (TGF)-b1 has been identified as the most potent mediator and convergent pathway in renal fibrosis. 4, 5 On TGF-b ligand binding, the type II receptor (TbRII) dimer and the type I receptor (TbRI) dimer form a stable complex, in which the TbRII phosphorylates the TbRI on serine-threonine residues in the GS domain. Activated TbRI then phosphorylates Smad2/3, which partner with Smad4 and translocate to the nucleus where they ultimately regulate gene transcription. [6] [7] [8] In addition to the Smad pathway, the activated TbRI also activates non-Smad signaling pathways, such as Akt, glycogen synthase kinase (GSK)-3b, and mitogen-activated protein kinases. [8] [9] [10] Both Smad and non-Smad pathways are known to contribute to TGF-b1-driven renal fibrosis. 9, 10 Heat shock protein (Hsp) 90 is one of the most abundant molecular chaperone proteins that are involved in protein folding and stabilization. 11 A variety of signaling proteins involved in cell survival, growth, and differentiation are known as Hsp90 client proteins. 11 Hsp90 requires several interacting co-chaperone proteins to exert its function on client proteins. On ATP-binding, the Hsp90-client complex associates with co-chaperones such as CDC37 and p23 to facilitate client stabilization. 12 In contrast, in its ADP-bound form, Hsp90 associates with different co-chaperones such as Hsp70 and Hop (Hsp70 and Hsp90 organizing protein), resulting in enhanced proteasomal degradation of the Hsp90 client proteins. 12 Hsp90 inhibitors suppress the progression of the Hsp90 complex toward the stabilizing form and shift it to the proteasome-targeting form, which result in ubiquitinproteasome degradation of the client. As Hsp90 inhibitors display remarkable selectivity for client oncoproteins, 13 several Hsp90 inhibitors are now in various stages of clinical developments as anticancer therapeutics. 12, 14 Interestingly, a recent study has identified TbRI and TbRII as Hsp90 client proteins. 15 However, the clinical significance of Hsp90 inhibitors in disease models with aberrant TGF-b responses remains to be determined. Here, we examined whether Hsp90 might regulate TGF-b1 signaling in renal cells and determined the effect of Hsp90 inhibitors in cultured renal cells and in a model of renal fibrosis.
MATERIALS AND METHODS Cell Culture and Treatments
Cells were purchased from American Type Culture Collection (Rockville, MD, USA). HK2 cells were cultured at 37 1C in a 5% carbon dioxide atmosphere in DMEM (Gibco, Grand Island, NY, USA) mixed 1:1 (vol:vol) with F12 medium (Gibco) supplemented with 10% FBS. NRK49F rat renal fibroblasts were grown in DMEM with 4.5 g/l glucose (Gibco) containing 5% bovine calf serum. Near confluent cells were incubated with serum-free media for 24 h to arrest and synchronize cell cycle. Before stimulation with recombinant human TGF-b1 (R&D Systems, Minneapolis, MN, USA), cells were pre-treated with 17-allylamino-17-demethoxygeldanamycin (17AAG) (LC Laboratories, Woburn, MA, USA), MG132 (Calbiochem, Darmstadt, Germany), Wortmannin (Sigma, St Louis, MO, USA), or PD98059 (Calbiochem) for the specified duration.
Animals
All animal studies were conducted with the approval of the Institutional Care and Use Committee of Soon Chun Hyang University Hospital in Seoul, Korea, and our study complied with the National Institutes of Health guidelines for the care and use of experimental animals. The unilateral ureteral obstruction (UUO) model was established in male CD1 mice that weighed 20-25 g (Charles River Laboratory, Wilmington, MA, USA). Briefly, after a mid-abdominal incision under anesthesia using tiletamine (15 mg/kg, Virbac Laboratories, Carros, France)/zolazepam (15 mg/kg, Virbac Laboratories)/ xylazine (9 mg/kg, Bayer, Korea, Seoul, Korea), the left ureter was isolated and ligated. Sham-operated mice were used as controls. 17AAG (2.5 and 25 mg/kg) or vehicle was administered by daily intraperitoneal injection immediately after ureteral ligation. After 2 weeks, the animals were killed and the kidneys were removed for various analyses.
Immunoblot Analysis
Tissue and cell lysates were centrifuged to remove cell debris, and supernatant was mixed with SDS loading buffer. Samples were then heated at 100 1C for 5 to 10 min before loading, separated through SDS-polyacrylamide gels, and subjected to western blot. Antibodies to E-cadherin (BD Transduction Laboratories, San Jose, CA, USA), a-smooth muscle actin (SMA) (Sigma), snail1 (Cell Signaling, Danvers, MA, USA), collagen I (Southern Biotech, Birmingham, AL, USA), phosphorylated Smad2 (Cell Signaling), Smad2/3 (Cell Signaling), phosphorylated Akt (Cell Signaling), Akt (Cell Signaling), phosphorylated GSK-3b (Cell Signaling), GSK-3b (Cell Signaling), phosphorylated extracellular signal-regulated kinase (ERK) (Cell Signaling), ERK (Cell Signaling), TbRI (Cell Signaling), and TbRII (Cell Signaling) were used. For fibronectin, peroxidase-conjugated rabbit anti-human fibronectin (DAKO, Glostrup, Denmark) was used. In some experiments, membrane fractionation was performed using commercially available kit (Pierce, Rockford, IL, USA).
Immunoprecipitation
For some experiments, membrane fraction of HK2 cell lysates was prepared according to the manufacturer's instruction (Pierce). Approximately, 1 mg of total proteins from membrane fraction or whole cell lysates were incubated overnight at 4 1C with anti-Hsp90 or anti-TbRII, followed by precipitation with 20 ml of protein A/G-Plus-Agarose (Santa Cruz) for 4 h at 4 1C. The precipitated complexes were immunoblotted with anti-Hsp90, anti-TbRII, or anti-ubiquitin.
siRNA Transfection An effective predesigned siRNA of Smurf2 (Applied Biosystems, Carlsbad, CA, USA) was selected through preliminary study. The sequences were as follows:
0 . Cells were transfected with siRNA (50 nM per well) using Lipofectamine (Invitrogen) reagent under serum-and antibiotic-free condition for 24 h and treated with TGF-b1. Several concentrations of siRNA were tested to determine the optimal knock-down conditions. Scramble RNAi was used as control. The transfection efficiency was determined using FAM-labeled Smurf2 siRNA (Applied Biosystems) by flow cytometry.
Histologic Analysis
The kidneys were initially perfused briefly with PBS through the heart to rinse away blood. Then, the kidneys were perfused with periodate-lysine-2% paraformaldehyde for 10 min, cut into slices of 1-to 2-mm thickness, and postfixed overnight in the periodate-lysine-2% paraformaldehyde solution at 4 1C. Paraffin-embedded sections (3 mm thickness) Hsp90 inhibitor reduces renal fibrosis H Noh et al were subjected to immunohistochemical staining and Masson's trichrome staining. Immunohistochemical staining was performed using anti-TbRII (Cell Signaling) and E-cadherin (BD Transduction Laboratories) antibodies. Masson's trichrome staining was performed according to the protocol provided by the manufacturer (Sigma). The positive area was quantitatively measured using Image Scope software (Aperio, Vista, CA, USA). For double immunofluorescence, rabbit polyclonal anti-aquaporin 1 antibody (1:500, Chemicon, Temecula, CA, USA) and mouse monoclonal anti-E-cadherin antibody (1:200, BD Transduction Laboratories) were mixed and then allowed to react overnight at 4 1C. After washing with PBS, labeling was visualized using FITC-conjugated donkey anti-rabbit antibody (1:1000, Jackson ImmunoResearch Laboratories, West Grove, PA, USA) and Cy3-conjugated donkey anti-mouse antibody (1:1000, Jackson ImmunoResearch Laboratories). Tissues were mounted in Vectashield mounting media (Vector Laboratories). Images were acquired using a Zeiss LSM 510 confocal microscope (Carl Zeiss).
Statistical Analyses
The mean values obtained from each group were compared by ANOVA with subsequent Fisher's least significant difference method. Unpaired two-tailed Student's t-test and nonparametric analyses were also used where appropriate. Data are presented as mean±s.e.m. A P-valueo0.05 was used as the criterion for a statistically significant difference.
RESULTS

Hsp90
Inhibitor Blocks TGF-b1-Induced ECM Production and EMT We first examined the effect of TGF-b1 on ECM production and EMT in HK2 human proximal tubular epithelial cells.
The dose of TGF-b1 was determined through a preliminary study. Treatment of HK2 cells with TGF-b1 (2 ng/ml) induced downregulation of their epithelial marker, E-cadherin ( Figures 1, 2a Hsp90 Inhibitor Blocks TGF-b1-Induced Smad and Non-Smad Phosphorylation As both Smad and non-Smad pathways have been implicated in TGF-b1-induced ECM accumulation and EMT, we next examined the effect of 17AAG on Smad and non-Smad intracellular signaling molecules. As shown in Figure 3 , TGF-b1 induced rapid and significant phosphorylation of Smad2, Akt, GSK-3b, and ERK. Phosphorylation of Smad2, Akt, and GSK-3b started to increase as early as 5 min and sustained until 1 h. Increased phosphorylation of ERK was detected as early as 15 min. As phosphorylation of Smad and non-Smad signaling molecules were continuously increased up to 1 h in our experimental setting, this time point was used in subsequent experiments. Pre-treatment with 17AAG significantly inhibited phosphorylation of Smad2, Akt, GSK-3b, and ERK in a time-dependent manner (Figures 4a and b) . This finding was similarly observed in NRK49F cells (Figures 4c and d) . 
Hsp90 inhibitor reduces renal fibrosis H Noh et al
To investigate how 17AAG suppresses Akt and ERK phosphorylation, we determined how long 17AAG took to reduce TGF-b1-induced Akt, GSK-3b, and ERK phosphorylation as compared with the phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin or the MAP kinase/ERK kinase inhibitor PD98059. As expected, treatment with wortmannin immediately blocked TGF-b1-induced phosphorylation of both Akt and GSK-3b (Figure 5a ). In contrast, a 1-to 2-h treatment with 17AAG did not significantly alter the phosphorylation of Akt and GSK-3b. 17AAG took 4 to 6 h to Similarly, TGF-b1-induced ERK phosphorylation was reduced immediately after PD98059 treatment, but only after 44 h of 17AAG treatment (Figure 5b ). These findings suggest that 17AAG may act via different mechanisms from known kinase inhibitors to block TGF-b1-induced signaling.
We next sought to determine whether 17AAG might decrease Smad and non-Smad phosphorylation via a mechanism dependent on ubiquitin-proteasome degradation. HK2 cells were treated with 17AAG in the presence or absence of MG132, a proteasome inhibitor, before TGF-b1 stimulation. As shown in Figures 6a and b , TGF-b1 significantly induced phosphorylation of Smad2, Akt, GSK-3b, and ERK. 17AAG effectively prevented all of these changes, but this 17AAG-mediated reduction was completely restored by simultaneous treatment with MG132, suggesting that 17AAG might decrease TGF-b1-induced Smad and non-Smad phosphorylation via a mechanism dependent on proteasome-mediated degradation. The inhibitory effect of 17AAG on TGF-b1-induced enhancement of snail1 expression was also restored by the treatment with MG132 (Figures 6a and b) . In contrast, a pathway that is not TGF-b1 dependent such as phosphatase and tensin homolog was not affected by MG132 (Figure 6c) , showing specificity for TGF-b1-dependent signaling.
Hsp90 Inhibitor Induces Degradation of TbRII As 17AAG inhibited multiple signaling pathways induced by TGF-b1 at the same time, we anticipated that 17AAG might block TGF-b1 signaling at or close to the receptor level. To examine the effect of 17AAG on the expression of TGF-b receptors, immunoblot analysis using membrane fraction was performed. As shown in Figure 7a , TbRI abundance did not change by the treatment with TGF-b1 or 17AAG. However, TbRII abundance was modestly but significantly induced by TGF-b1 and reduced by 17AAG. Furthermore, immunoprecipitation analysis revealed that the interaction between Hsp90 and TbRII was significantly decreased by 17AAG, and which was almost completely restored by simultaneous treatment with MG132 (Figure 7b ). In addition, 17AAG resulted in more pronounced formation of polyubiquitinated, higher-moleculer-weight forms of TbRII in the presence or absence of MG132 (Figure 7c ). These data indicate that 17AAG probably blocks the interaction between Hsp90 and TbRII and subsequently induces ubiquitin-proteasome degradation of TbRII.
Hsp90 Inhibitor-Induced Downregulation of TGF-b1-Signaling is Mediated by Smurf2
Ubiquitin-proteasome degradation has been implicated in the regulation of the stability of the TGF-b receptor complex. As Smurf2 has been shown to be an E3 ubiquitin ligase for TbRII, 16 we next tested whether siRNA targeting Smurf2 can block 17AAG-mediated downregulation of TGF-b1-signaling. With 96.7% of transfection efficiency of siRNA (Figure 8a ), Smurf2-specific siRNA could efficiently knockdown Smurf2 protein expression by 44% (Figure 8b ). As shown in Figure 8c , Smurf2 siRNA restored TbRII expression in the membrane. In parallel, the ability of 17AAG to inhibit Smad2, Akt, and ERK phosphorylation-induced by TGF-b1 was reversed by Smurf2 siRNA compared with scrambled oligonucleotides (Figures 8c and d) . These results suggest that Smurf2 is required for 17AAG-mediated downregulation of TGF-b1 signaling. 
Hsp90 inhibitor reduces renal fibrosis H Noh et al
Hsp90 Inhibitor Blocks Renal Fibrosis in Obstructed Kidney
To investigate the ability of Hsp90 inhibitor to suppress renal fibrosis in vivo, we examined the effect of 17AAG on ECM accumulation and the expression of TbRII in UUO kidneys. 17AAG was administered into mice by daily intraperitoneal injection at 2.5 or 25 mg/kg body weight for 14 days. We observed significant increase in expression of a-SMA, fibronectin, and collagen I in the UUO kidneys ( Figure 9 ). We also observed increased expression of snail1 (Figures 9a  and b) . Treatment with 17AAG attenuated the induction of snail1, as well as a-SMA, fibronectin, and collagen I in UUO kidneys while it had no effect in sham controls ( Figure 9 ). In contrast, E-cadherin expression was significantly decreased in renal tubules of UUO kidneys as compared with control ( Figures 9a, b, and 10b ). 17AAG almost completely restored E-cadherin expression in a dose-dependent manner ( Figures  9a, b, and 10b) . Phosphorylation of Smad2 induced by UUO was significantly decreased by the treatment with 17AAG, suggesting that all of these changes were TGF-b1 dependent (Figures 9c and d) . As we used proximal tubular cells in our in vitro studies, we performed parallel studies of proximal tubules with double staining for proximal tubular marker aquaporin 1 and E-cadherin. In control mice, E-cadherin expression was strongly positive in aquaporin 1-negative cells, however, E-cadherin-positive proximal tubular cells 
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could be identified. We observed that UUO reduced E-cadherin expression in proximal tubular cells and that 17AAG restored it (Figure 10e ). Of note, immunohistochemical staining revealed that UUO kidneys have increased expression of TbRII and that 17AAG effectively prevented UUOinduced enhancement of TbRII by 52% and 78% at 2.5 and 25 mg/kg, respectively (Figures 10a and d) . Finally, UUO caused a marked increase in collagen accumulation, as shown by Masson's trichrome staining (Figures 10c and d) . Treatment with 17AAG, however, reduced collagen deposition (Figures 10c and d) . Together, these in vivo results indicate that administration of 17AAG suppresses UUO-induced TbRII expression and reduces ECM accumulation and renal fibrosis.
DISCUSSION
In this study, we have demonstrated that an Hsp90 inhibitor suppresses TGF-b1-induced Smad and non-Smad signaling via a mechanism dependent on proteasome-mediated degradation of TbRII. Smurf2 appears to be essential for Hsp90 inhibitor-induced degradation of TbRII because Smurf2 deficiency reversed the ability of the Hsp90 inhibitor to block 
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TGF-b1 signaling. Furthermore, this study, for the first time, clearly showed the therapeutic effects of Hsp90 inhibitor in a model of renal fibrosis. Hsp90, which accounts for 1-2% of cytosolic proteins, controls the folding and intracellular trafficking of diverse cellular proteins involved in several signal transduction pathways. Hsp90 has been shown to form complexes with many cellular proteins that are important for cell growth, survival, and differentiation. 11 As numerous oncoproteins have been shown to be Hsp90 client proteins, more than a dozen Hsp90 inhibitors are currently undergoing clinical evaluation in cancer patients. 14 As 17AAG has less toxicity and higher selectivity for client proteins, 17AAG is the first Hsp90 inhibitor to enter clinical trials. Other than the cancer area, Hsp90 inhibitors have also been shown to be effective as neuroprotective agents in animal models of Parkinson disease, 17 stroke, 18 autoimmune encephalitis, 19 and spinal and bulbar muscular atrophy. 20 In this study, we have shown the efficacy of 17AAG in tubulointerstitial fibrosis induced by UUO, and considerably extended the therapeutic application of 17AAG beyond cancer and inflammatory and degenerative diseases.
TGF-b1 has been identified as the single most important growth factor that can induce and mediate renal fibrosis. 4, 5 Upregulation of TGF-b1 is a common finding in virtually every type of progressive chronic kidney disease, in both animals and humans. In cell culture systems, TGF-b1 stimulates mesangial cells, 21 interstitial fibroblasts, 22, 23 and tubular epithelial cells 9, 10, 24 and induces matrix expression through its interaction with TGF-b receptors. Thus, TGF-b1 has been studied as a target to prevent the progression of renal fibrosis. Previous studies showed that anti-TGF-b strategies with natural inhibitor, monoclonal antibody or antisense oligonucleotides could attenuate kidney injury. [25] [26] [27] However, none of these strategies has been implemented Immunoprecipitation analysis using membrane fraction revealed that the interaction between Hsp90 and TbRII was significantly decreased by 17AAG, which was almost completely restored by simultaneous treatment with MG132. Cells were treated with 17AAG for 6 h and then stimulated with TGF-b1 (2 ng/ml) for 1 h. Cells were cotreated with MG132 in parallel with 17AAG as indicated. Data are mean±s. clinically so far because of the potential of untoward inhibition of the anti-inflammatory actions of TGF-b1. 28 Therefore, from a clinical point of view, it is important to develop alternate novel therapies to more specifically suppress downstream targets of maladaptive TGF-b signaling events with relatively low toxicity. Our data showing the ability of 17AAG to inhibit TGF-b1-induced Smad and non-Smad targets in renal tubular epithelial cells and fibroblasts suggested that this Hsp90 inhibitor could negatively regulate TGF-b signaling at a convergent point such as the TGF-b receptor complexes. Indeed, we show that TbRII interacts with Hsp90 and that the Hsp90 inhibitor blocks their interaction, and subsequently promotes the ubiquitination and degradation of TbRII. Although regulation at the level of the receptor and its role in the complexity of the TGF-b response has not been extensively studied, the availability and function of TGF-b receptors are crucial determinants of TGF-b signaling.
Upregulation of TbRII has been shown in experimental animal models of type 1 29 and type 2 diabetic kidney disease. 30 A similar finding has been observed in UUO kidneys. 22 In support of this finding, we demonstrated that TbRII expression is significantly increased by UUO and that the treatment with 17AAG effectively prevents the enhancement of TbRII abundance.
Recent progress has shown that TGF-b receptors are subject to post-translational modifications such as ubiquitination, phosphorylation, and sumoylation. 31 Phosphorylation of TbRI by TbRII enables the interaction with signaling molecules including Smad and non-Smad pathways, leading to the activation of TGF-b responses. 6, 7 Sumoylation results in the covalent attachment of a SUMO polypeptide to a lysine residue in the cytoplasmic domain of the TbRI. 32 Sumoylation of TbRI facilitates recruitment of Smad2/3 and enhances Smad signaling. 32 In contrast, the role of ubiquitination is to mediate degradation of the TGF-b receptor complex, Figure 8 Hsp90 inhibitor 17AAG-induced downregulation of TGF-b1 signaling is mediated by Smurf2. (a) Transfection efficiency was determined by flow cytometry using FAM-labeled Smurf2 siRNA. (b-d) Effect of Smurf2 silencing on TGF-b1 signaling. HK2 cells were transfected with scramble control siRNA (C-siRNA) or Smurf2 siRNA using Lipofectamine reagent for 24 h and treated with 17AAG for 6 h. TGF-b1 (2 ng/ml) was added for 15 min (Akt and ERK) or for 1 h (Smad and TbRII). The protein levels for Smurf2, Smad2/3, phosphorylated Smad2, Akt, phosphorylated Akt, ERK, and phosphorylated ERK were analyzed by immunoblot analysis using whole cell lysates. Membrane fraction was used for TbRII immunoblot analysis. Data are mean ± s. 16, 34 As it has been reported that Smurf1 deficiency did not alter the degradation or availability of TGF-b receptors, 35 we focused on Smurf2 in our study. Our observations showing the ability of 17AAG to inhibit TGF-b signaling was reversed by Smurf2 siRNA along with restoration of TbRII clearly indicate that the Hsp90 inhibitor promotes Smurf2-mediated degradation of TbRII.
In this study, the levels of phospho-Akt, phospho-GSK-3b, and snail1 of cells treated with 17AAG (but not with TGF-b1) were significantly increased by co-treatment with MG132, as shown in Figures 6a and b . We speculate that this is because of the effect of the Hsp90 inhibitor on the upstream Akt kinase, 3-phosphoinositide-dependent protein kinase-1 (PDK1). PDK1 is a kinase responsible for phosphorylation of Akt 36 and is one of the Hsp90 client proteins. 37 Therefore, in addition to the effect on the expression of TbRII, a presumed 
17AAG-induced degradation of PDK1 might be effectively restored by co-treatment with MG132. It is known that increased activation of Akt induces GSK-3b phosphorylation, 9 leading to the stabilization of snail1. 38 The toxic effects of 17AAG have not been addressed in this study. However, it has been documented that 25-week-old mice treated with 25 mg/kg 17AAG three times a week for 20 weeks were free from obvious side effects. 20 There are now many drug candidates that target Hsp90 as both intravenous and oral therapeutics. 14 The most advanced product is 17AAG in a phase 3 clinical trial in combination therapy for the treatment of multiple myeloma. 14 Therefore, once the safety issue is cleared, this Hsp90 inhibitor would be a good candidate as an anti-fibrotic therapeutic.
In conclusion, this study demonstrates that an Hsp90 inhibitor prevents the development of renal fibrosis induced by TGF-b1 via a mechanism dependent on Smurf2-mediated degradation of TbRII. These data suggest that a new therapeutic strategy based on Hsp90 inhibition may prove beneficial in chronic kidney diseases. 
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